ArticleFrontiers in oncology2025
Comparison of Albumin-Bilirubin, Platelet-Albumin-Bilirubin, and Child-Pugh scores to predict overall survival in patients with stage C hepatocellular carcinoma with liver cirrhosis treated with c-TACE.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Child-Pugh Stage Predicts Survival in Hospitalized Patients with Decompensated Cirrhosis: A 10-Year Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Albumin-Bilirubin and Platelet-Albumin-Bilirubin scores as predictors of all-cause long-term mortality in intermediate-high-risk pulmonary embolism.Irish journal of medical science · 2026Article
- Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2026Review
- NLR-PALBI Score and Its Grading: Predicting Overall Survival of Patients with Primary Liver Cancer Undergoing Transcatheter Arterial Chemoembolisation.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate and compare the prognostic performance of Albumin-Bilirubin (ALBI), Platelet-Albumin-Bilirubin (PALBI), and Child-Pugh (CP) scores in predicting overall survival (OS) among patients with stage C hepatocellular carcinoma (HCC) with liver cirrhosis undergoing conventional transcatheter arterial chemoembolization (c-TACE). Methods: We performed a retrospective cohort analysis of 151 cirrhotic patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC treated with c-TACE between 2017 and 2021. Pretreatment CP scores, ALBI, and PALBI were recorded, and their associations with OS were analyzed using Kaplan-Meier methods and receiver operating characteristic (ROC) curve analysis. Multivariate Cox models were used to determine independent survival predictors. Results: The median OS for the entire study cohort was 18.8 months (95% CI: 11.294-26.306 months). CP score, ALBI grade and PALBI grade were significantly correlated with OS (all P<0.05). Survival analysis revealed dose-dependent relationships: CP classes A and B demonstrated median OS of 22.9 vs 9.9 months (P<0.05), ALBI grades 1-3 corresponded to median OS of 25.7, 12.7, and 3.8 months respectively (P<0.05), PALBI grades 1-3 showed median OS of 25.7, 10.1, and 8.5 months (P<0.05). The area under the receiver operating characteristic curve (AUROC) values of CP score, ALBI grading, ALBI score, PALBI grading and PALBI score were 0.572, 0.550, 0.595, 0.619 and 0.637, respectively. Compared with the CP score and ALBI, PALBI showed a better predictive effect in patients with stage C hepatocellular carcinoma with cirrhosis treated with c-TACE. Multivariate analysis showed that CP grade, ALBI grade, PALBI grade, Portal vein invasion, and the number of c-TACE were independent predictors affecting the survival period of patients. Conclusion: In cirrhotic patients with BCLC stage C HCC undergoing c-TACE, the PALBI scoring system emerged as a more reliable prognostic indicator than CP and ALBI assessments, showing enhanced discriminative capacity for survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.